Despite the high incidence and mortality rate of prostate cancer, the molecular mechanisms underlying the progression of the disease remain to be fully elucidated. This paper reviews the current state of knowledge on prostatic carcinogenesis, focusing not only on the molecular genetics of prostate cancer, but also on the role of oncogenes, tumour suppressor genes, and growth factors. The remarkable ability of prostate cancer cells to survive androgen withdrawal and apoptosis are discussed, with particular emphasis on how apoptosis may be manipulated from a therapeutic viewpoint.
Introduction
Prostate cancer is the most common malignancy in men and one of the most common causes of death from cancer. 1 Prostate tumours, although initially androgen dependent, inevitably progress to an androgen-independent phenotype after treatment with androgen deprivation. The events that characterise this progression of the disease remain poorly understood. If prostate cancer begins as a clone of androgen-dependent cells, which only upon androgen deprivation become androgen-independent, then the androgen-independence may arise as a result of androgen deprivation therapy. 2 Alternatively, androgen-independent cells may already be present at diagnosis. Androgen deprivation therefore creates an environment where only these cells may survive and proliferate, thereby becoming the predominant cell type. Eventually, the tumour will be composed of only androgen-independent cells, and clinical androgen-independence arises. 2 The second hypothesis is supported by experimental evidence from a number of animal models. 3 ± 5 The remarkable ability of some prostate cancer clones to survive androgen withdrawal and apoptosis has, consequently, led to a search for the pathways that allow prostate cancer cells to survive, therefore avoiding apoptosis.
Epidemiology and natural history of prostate cancer
A striking phenomenon in prostate cancer epidemiology is that the prevalence of latent prostate tumours in most populations is similar, but the rates for clinical prostate cancer vary from one population to another. 6 The disease is more frequent in black Americans than white and is rare in oriental men, especially those living in their country of origin. 7 Such discrepancies cannot be completely explained by genetic factors, therefore providing compelling evidence that many incidences of prostate cancer may be a consequence of lifestyle and/or environment and are therefore possibly preventable. A number of studies have suggested that racial differences in dietary fat intake, circulating levels of testosterone, intraprostatic activity of 5-a reductase, and polymorphisms of the androgen receptor (AR) gene might partly account for such discrepancies. Other than age, family history of prostate cancer, race and geographical area of residence, risk factors for prostate cancer are unknown. 6 Prostate cancer is a remarkably heterogeneous disease. Some tumours are very small, well-to-moderately differentiated and con®ned to the prostate. Only a minority of these carcinomas, similar to those found at autopsy, will ever progress to become life-threatening, unless left without intervention for decades. 8 `C linically important' carcinomas are larger, or of higher grade, or more extensive, and are much more likely to invade and metastasise, leading to the eventual death of the patient. 9 The risk to life and health posed by early stage carcinoma has been dif®cult to assess, mainly due to the relatively slow growth rate and long doubling times of such carcinomas, averaging 2 ± 4 y. 10 Prostate cancer is often detected in elderly men (median age, 71 y) whose high rate of comorbid conditions means that they can die before the disease manifests itself. Indeed, autopsy studies have shown that 30% of men over 50 y of age have histological evidence of so-called`latent prostatic cancer', which remains undetected during the patient's lifetime. 11 In fact, only 1 in 4 of these carcinomas will become clinically evident, and only 1 in 14 will prove fatal. 8 When early stage prostate carcinoma is detected clinically it is dif®cult to predict its course of evolution and accurately determine the probability of progression and metastasis over time. Because it could be argued that many men die`with' rather than`from' prostate cancer, there are proponents of both conservative management (watchful waiting) and de®nite treatment for clinically localised prostate cancer. However, there is a clear need for further research to develop better ways to characterise the threat posed by prostate carcinomas detected early in asymptomatic patients, and to effectively treat these tumours with new modalities which have less impact on quality of life than is currently possible.
Molecular biology of prostate cancer
The transformation of normal cells into malignant cells involves many changes, since cancer cells can differ from their normal counterparts in morphology, dependence on growth factors, survival factors, and in a variety of other biochemical functions. Multistep carcinogenesis is, therefore, a widely accepted model for cancer progression and has been readily demonstrated in the case of prostate cancer in rodent models. 12 Thompson et al 12 have shown that expression of the oncogene Ras in normal prostate cells of the mouse is insuf®cient for transformation, and that over-expression of a second oncogene, Myc, is necessary before transformation becomes a frequent event. However, not all cells become transformed, suggesting that additional events, such as the inactivation of tumour suppressor genes, activation of additional oncogenes and deregulation of growth factors are required for full transformation.
The concept of multistep carcinogenesis suggests that latent prostate cancers, as well as putative precursor lesions, such as prostatic intraepithelial neoplasia (PIN), have undergone a subset of events which are insuf®cient to give rise to the fully malignant phenotype. 13 In addition, this concept also suggests that speci®c and discrete genetic alterations may be associated with different stages, and grades of prostate cancer. Although this is an attractive hypothesis, and certain speci®c events have been strongly associated with progression of prostate cancer (for example, altered p53 status, AR mutations, Bcl-2 overexpression), none have been consistently associated with any particular stage, or grade of prostate cancer. It is likely that the accumulation of multiple genetic alterations leads to the development and progression of prostate cancer. Characterisation of such events is of key importance for the understanding of prostate cancer progression, and for the development of new strategies for the management and treatment of prostate cancer.
Hereditary prostate cancer
Although evidence demonstrating familial clustering of prostate cancer was available in 1960, 14 prostate cancer was not widely recognised as a familial cancer. Indeed, prostate cancer was later shown to have higher familiarity than both colon and breast carcinoma. 15 Segregation analysis has demonstrated that prostate cancer could be separated into familial and true hereditary prostate cancer. 16 The later is a rare disorder ( $ 9% of all prostate cancers) and has a dominant Mendelian inheritance with high penetrance. Familial clustering could easily re¯ect a shared environmental risk factor as a genetic mechanism. Twin studies, however, have provided further evidence that at least in some cases the disease may be truly hereditary. 17 The genetic epidemiology of prostate cancer is complex, and genes on chromosome 1 and X chromosome have been shown to contribute to familial aggregation (reviewed in reference 18). Whereas the susceptibility locus found by Smith et al 19 was located at 1q24-q25 (HPC1), Berthon et al 20 found by linkage a second putative predisposing gene for prostate cancer located on 1q42.2-q43 (PCAP), signi®cantly distant from the previously proposed locus. Xu et al 21 have presented evidence for a prostate cancer susceptibility gene located on Xq27-q28. A candidate prostate cancer susceptibility gene on the X chromosome is the AR gene. However, the AR gene is located at Xq11-12. 22 
Chromosomes gains and losses
The search for speci®c genetic changes associated with prostate cancer has failed to reveal a single high-frequency event (with, perhaps, the exception of prostate speci®c antigen, PSA, overproduction). Cytogenetic and loss of heterozygocity studies have, however, pointed to several regions of the human genome that could contain tumour suppressor genes involved in the aetiology of prostate cancer. 1 Losses are ®ve times more common than gains. 23 Frequent deletions at loci on chromosomes 8p, 10pq, 13q, 16q and18q have been observed in prostate cancer. 1 In tumours failing to respond to androgen ablation, the number of losses and gains is signi®cantly greater than in primary tumours, with loss of 8p (78%) and gains of 8q (89%), X (56%), and 7 (56%) being particularly common (reviewed in reference 23). Allelic loss at 8p22 has been repeatedly demonstrated in prostate cancer by several groups, and allelic imbalance studies on microdissected tumours have identi®ed additional sites of deletion on this chromosome located in the region of 8p12-21 24 ± 26 Concomitantly, evidence for increased copy numbers of sequences on the long arm of chromosome 8 have been observed in a subset of prostate tumours with loss of 8p sequences, 13 suggesting the presence of an activated oncogene on this chromosome as well. An obvious candidate gene that may be the target of these ampli®cation events is the Myc gene located at 8q24. Interestingly, Myc overexpression has been observed in prostate cancers, as well as in other tumours. 27 A candidate tumour suppressor gene MXI1 (MAX-interacting protein-1), a negative regulator of Myc, was identi®ed within 10q24-25. 28 This mutation is, however, rare suggesting that this gene does not play a key role in prostatic carcinogenesis. 23 Sanchez et al 29 have de®ned a novel genetic locus within chromosome 10pter-q11, designated PAC1, for prostate adenocarcinoma 1, involved in tumour suppression and apoptosis of human prostate carcinoma. However, losses of chromosome 10q, a well as of chromosome 17p (p53), usually occur late in the disease process. 1 The loss of chromosome 13q (RB1) is a common and probably an early event in prostate cancer, but it has been shown that losses on 13q occur equally proximal or distant to RB1. 1 There is growing evidence that a critical event in the progression of a tumour cell from a non-metastatic to metastatic phenotype is the loss of function of metastasissuppressor genes. KAI1 is a metastasis suppressor gene which has been localised to chromosome 11p11.2. 30 KAI1 has been shown to be evolutionarily conserved, expressed in many human tissues, and to encode a member of a structurally distinct family of leukocyte surface glycoproteins. 23 The expression of the KAI1 gene has been found to be downregulated during the tumour progression of prostate, breast, lung, bladder, and pancreatic cancers in humans, and this downregulation appears to be at posttranscriptional level. 31 Recently, p53 has been shown to directly activate the KAI1 gene, suggesting that loss of p53 function can lead to the downregulation of KAI1, which may result in the progression of metastasis. 32 Deletions of 16q are of interest since it carries the Ecadherin gene. 33 Loss of E-cadherin is likely to promote metastasis, as the E-cadherin is involved in cell ± cell adhesion. 34 Indeed, E-cadherin levels were shown to be often reduced, or absent in cancer cell lines; such lines were frequently more ®broblastic in morphology and invasive in experimental assays. 35, 36 Importantly, loss of regions in chromosome 16q were observed in 70% of patients with metastatic prostate cancer compared 35% of patients with localised disease. 37 
DNA methylation
Genetic imprinting is believed to play an important role in prostate cancer aetiology. Indeed, three important genes in prostate cancer have been shown to be silenced by DNA methylation when compared with those in normal tissue, namely E-cadherin, glutathione-S-transferase (GST), and AR. 38 In a study by Lee et al, 39 CpG islands of the promoter region of GST p were shown to be methylated in >96% of human prostate cancer tissues analysed, while they were not methylated in either adjacent normal tissues, or in benign prostatic hyperplasia (BPH) tissues. This is the most commonly reported genomic change in prostate cancer, suggesting that possibly during the lifetime of the cancer clone, this important cellular defence mechanism has been shut down. 13 Interestingly, it has been shown that this DNA methyl group can be removed and that the enzyme can be regulated by diet. 39 DNA methylation of the promoter regions of E-cadherin has been shown to downregulate this protein in cancer cells. 40 Because E-cadherins are transmembrane proteins that anchor the cytoskeleton of the cell to that of the neighbouring cell, perturbances of E-cadherin are thought to be associated with more aggressive prostate cancers and increased invasive capacity of cancer cells. 34, 40, 41 Prostate growth and development is clearly regulated by androgens, the effects of which are mediated by the AR. The human AR gene is located on the X chromosome (Xq11-12). 22 The AR has been reported to be frequently modi®ed in patients with prostate cancer. 42 One of the key modi®cations may relate to a glutamine-repetitive sequence occurring in the receptor, which appears to vary in length among those of Asian descent, Caucasians and African men. 38 The length of a polymorphic CAG repeat sequence, occurring in the androgen receptor gene, has been shown to be inversely correlated with transcriptional activity by the AR, and the shortest repeats are thought to be associated with more aggressive cancers. 42, 43 The trinucleotide expansion has been shown to affect the AR function for example, by weakening its transactivation properties), which is believed to confer variable androgenicity upon the prostate over time. 44 Therefore, it seems that the effect of androgen can either by increased or decreased depending on the properties of the AR, and this may represent a novel mechanism for androgen resistance. In addition, altered DNA methylation patterns have been frequently found in prostate cancers, suggesting widespread alterations in methylation-modulated gene expression. 45 Methylation of the androgen receptor promoter CpG island has been shown to be associated with loss of androgen receptor expression, and it has recently been shown that exposure of AR-negative prostate cancer cell lines to 5-aza-2 H deoxycytidine, a demethylating agent, induced the reexpression of AR RNA. 46 Importantly, tumour suppressor genes can also be inactivated by methylation. Such a mechanism can account for heritable inactivation of a tumour suppressor without any alteration of the gene sequence or organisation. For example, Sakai et al 47 have shown that the RB gene was methylated in some retinoblastomas, thus causing its repression. Hence, altered DNA methylation patterns may have a critical role in determining the overall pattern of gene expression in prostate cancer tissue. This mechanism, together with a mutational mechanism, may account for the inactivation of a variety of proliferationand apoptosis-regulatory genes.
Tumour suppressor genes
As with other neoplasms, mutations of tumour suppressor genes and oncogenes are likely to contribute to the genesis of prostate cancer. Indeed, a number of studies have investigated the p53 and RB tumour suppressor genes in prostate cancer.
p53
The p53 gene is located on the short arm of chromosome 17 and encodes a 53 kDa nuclear phosphoprotein. Often referred to as the guardian of the genome, p53 causes a G 1 -S cell cycle arrest in cells exposed to DNA-2 damaging agents which presumably allows the cell suf®cient time to repair or restore its DNA damage before replication in S phase, or, depending on the damage, induce apoptosis. 48 The cell cycle arrest is mediated by a posttranscriptional accumulation of p53 protein and by subsequent activation of downstream targets (for example, p21 CIP1aWAF-1 and GADD 45). 49 The mechanisms by which p53 induces apoptosis are still poorly understood. There is evidence that p53 can in¯uence the expression of BCL-2 family members (see Oncogenes section). A p53 negative response element has been mapped in the BCL-2 gene, and a p53 binding site in the BAX gene has been shown to transactivate the BAX promoter. 50, 51 Hence, P53 may induce apoptosis by modulating the ratio of Bcl-2 family members dimers, towards cell death. FAS expression can also be induced by P53, which can potentially increase cell susceptibility to apoptosis. 52 When p53 is inactivated, DNA alterations can accumulate leading to the progression of cells into a malignant phenotype. In addition, inactivating mutations of p53 have been shown to confer resistance to apoptosis induced by radiation and multiple chemotherapeutic agents. 53 Abnormalities of the p53 tumour suppressor common genetic alterations are associated with human malignancy. Although p53 mutations in primary prostate cancers tissues are relatively infrequent, they occur at signi®cant levels in metastatic disease. 54 Almost all of the p53 mutations are associated with high-grade, metastatic, or hormone-refractory prostate cancer (HRPC). 55 ± 57 Mutations in BPH are rate. 58 Therefore, p53 mutations are not only late events in prostate tumour development, but are also less frequent (10 ± 20%) than in other types of cancer. 56 
RB
The RB gene is the second most mutated tumour suppressor in human cancers. It is located on chromosome 13p and encodes a 110 kDa nuclear phosphoprotein, which has been implicated in the regulation of cell cycle progression. 59, 60 Although further studies are required to fully assess the precise role of RB alterations in prostate carcinogenesis, studies carried out thus far suggest that it is infrequently mutated in prostate cancer, 61 and that abnormal Rb expression has little prognostic signi®cance in prostate cancer. 51 
BIN1
The human BIN1 gene has been mapped to chromosome 2q14, 63 within a mid-2q region which is deleted in 42% of metastatic prostate cancers. 64 BIN1 is a putative tumour suppressor identi®ed in human cells as a short-lived monomeric 70 kDa phosphoprotein with a putative nuclear localisation motif. 65 It was originally identi®ed through its interactions with Myc. 66 Because BIN1 is phosphorylated in vivo, its functions may be regulated by changes in phosphorylation status. If this is the case, the function of a Myc ± BIN1 complex may be regulated post-translationally. 67 Further studies must be carried out to determine whether the phosphorylation status of BIN1 affects its Myc-dependent and independent growth-inhibitory activity. There is evidence that several forms of BIN1 may be present in cells, and indeed alternative splicing of BIN1 has been demonstrated. 67 Interestingly, the localisation of cellular BIN1 varies considerably in normal and malignant cells. 68 In normal cells, where growth is regulated, BIN1 is mainly nucleoplasmic, but was also present in a subnuclear compartment. In a panel of tumour cells that expressed BIN1, the predominant location was the subnuclear compartment. The precise role of BIN1 in prostate cancer development remains, however, to be fully elucidated.
PTEN
Mapping of homozygous deletions on human chromosome 10q23 has led to the identi®cation of a candidate tumour suppressor gene, PTEN, that appears to be mutated in a variety of cancers including prostate cancer. 68, 69 PTEN is a cytoplasmic protein, which shares extensive homology with tensin, a cytoskeletal protein localised to focal adhesions, and with auxilin, a protein involved in synaptic vesicle transport. 70 PTEN (MMAC1aTEP1) encodes a dual speci®city phosphatase, which has been shown to dephosphorylate focal adhesion kinase (FAK), and to inhibit integrin-and growth factormediated mitogen-activated protein kinase (MAPK) signalling pathways, both of which have been associated with cell spreading and cell migration. 71, 72 Therefore, PTEN phosphatase may function as a tumour suppressor by negatively regulating cell interactions with the extracellular matrix. There is also evidence that PTEN may exert its tumour suppressor functions by negatively regulating PKB/Akt, a crucial regulator of cell survival. 73, 74 Indeed, tumours associated with loss of heterozygosity in PTEN showed elevated phosphorylation of PKB. 75 A number of studies have shown that PTEN is mutated in a signi®cant proportion of prostate carcinomas, especially metastatic prostate cancers. 76 ± 79 Dong et al 80 have shown that PTEN mutations occur at low frequency in most low stage prostate carcinomas they have analysed, and Feilotter et al 81 have shown that mutation of PTEN is either a late event in prostate tumourigenesis, or that another tumour suppressor important in prostate cancer may lie close to PTEN in 10q23. Therefore, more studies need to be conducted to establish the relevance of PTEN alterations in prostatic carcinogenesis. Given that inactivations of tumour suppressor genes on chromosome 10 are associated with advanced prostate cancer, these genes are attractive candidates both as prognostic markers and as potential targets for therapeutic intervention. 82 Oncogenes A number of oncogenes have been examined in prostate cancer, including Bcl-2, RAS, MYC, and ERB2. Aberrant expression of these oncogenes has been detected in prostate cancer cells, compared to expression in normal tissue. However, none of these genes have been shown to be consistently activated, and the overexpression mechanisms remain largely unde®ned. 13 
Bcl-2
Amongst the most important regulators of apoptosis are the Bcl-2 family members (reviewed in reference 83). The expression of these genes frequently becomes altered in human cancers, thus contributing to neoplastic cell expansion by prolonging cell survival. 84 The BCL-2 gene is located on chromosome 18q21 and was identi®ed due to its involvement at the breakpoint of the t(14;18) interchromosomal translocation commonly found in human follicular B cell lymphomas. 85 This translocation combines the BCL-2 locus and the immunoglobulin heavy chain locus, resulting in the overexpression of Bcl-2. There is a strong body of evidence that Bcl-2 overexpression causes resistance to chemotherapeutic drugs and radiation, while decreases in its expression promote apoptotic responses to chemo-and radiotherapy. 86, 87 The BCL-2 gene encodes a 26kDa protein, which is located primarily in the outer mitochondrial membrane, nuclear envelope, and parts of the endoplasmic reticulum. 88, 89 Bcl-2 family proteins share structural similarity with the pore-forming domains of certain bacterial toxins, and some of these proteins have been shown to form channels in synthetic lipid membranes. 90 One of the most interesting aspects of the Bcl-2 family is their ability to interact with each other and form homo-and heterodimers (reviewed in reference 83). To date, 14 cellular homologues of Bcl-2 have been identi®ed, including the anti-apoptotic proteins Bcl ± X L , Mcl ± 1, A1aB¯-1, Bcl-W, Nr-13 (avian) and Ced ± 9 (nematode), and the pro-apoptotic members Bax, Bcl-X S, Bad, Bik and Bid. 83 Additional homologues (for example BRAG-1) have been identi®ed, but their effects on survival and death have not yet been assessed. The antiapoptotic activity of Bcl-2 is thought to be dependent, at least in part, on its ability to heterodimerize with Bax. Importantly, drug-induced damage to DNA results in p53-dependent increase in Bax, and conversely, cells overexpressing Bcl-2 are protected against p53-induced elevations in Bax. 50, 51 It has been shown that overexpression of Bcl-2 had no effect on the entry of chemotherapeutic drugs into tumour cells, and that the drugs were still able to interact with their targets inducing DNA damage and cell cycle arrest. 91 Therefore, Bcl-2 de®nes a novel type of drugresistance mechanism, which does not involve MDR-1, DNA repair enzymes, or glutathione overproduction. Rather than blocking the primary injury, Bcl-2 inhibits the cellular damage from being translated into a death signal. Hence, it converts the effect of chemotherapeutic drugs from cytotoxic to cytostatic. 91 Immunohistochemical analysis of Bcl-2 levels in prostate tumours has revealed a correlation between the presence of Bcl-2 and resistance to anti-androgen therapy. 92, 93 Expression of Bcl-2 was shown to be augmented following androgen ablation and it correlated with the progression of prostate cancer from androgen-dependence to androgen independence. McDonnell et al 92 have shown that within the androgen-dependent tumours the expression of Bcl-2 was heterogeneous with the majority of cases exhibiting undetectable levels of Bcl-2. However, several cases of androgen-dependent prostate cancers exhibited moderate levels of Bcl-2. In contrast, with the exception of bone marrow metastases, androgen-independent cancers possessed detectable levels of Bcl-2, which was characteristically present at high levels, and was diffusely distributed throughout the tumour. Therefore, Bcl-2 expression is not a primary molecular event but rather a secondary event associated with progression in tumour recurrences following androgen ablation. Krajewski et al 89 have examined the expression of other Bcl-2 family members, and shown that expression of BCL-X and MCL-1 also increases during the progression of many prostate cancers, whereas the expression of BAX remains comparatively constant. Therefore, during the evolution to androgen independence and metastatic disease, prostate cancers may become progressively more resistant to apoptosis, at least in part, due to altered ratios of Bcl-2, Bcl-X L and Mcl-1 relative to Bax.
Phosphorylation of Bcl-2 has also been shown to play a role in its regulation, and there is evidence that it may be involved in the inactivation of Bcl-2's anti-apoptotic function. 94, 95 Phosphorylation of Bcl-2 at serine residues results in decreased binding to Bax and in its inactivation. 94 Recently, Maundrell et al 96 have shown that Bcl-2 undergoes phosphorylation by SAPKaJNK. Since the SAPKaJNK cascade generally leads to apoptosis, these studies raise the interesting possibility that Bcl-2 may also be a target substrate in pathways controlling cell death. 96 In addition, drugs that damage the integrity of microtubules (for example, taxol, vincristine) induce Bcl-2 phosphorylation in the G 2 -M phase of the cell cycle, suggesting the possible involvement of a microtubule associated kinase or a cyclin-dependent kinase that becomes active during mitosis. These results also provide evidence for a physiological role of Bcl-2 as the`guardian of microtubule integrity'. 95 Because HRPC often overexpress Bcl-2, and because a positive response to taxol seems to be strictly dependent on Bcl-2 expression, these ®ndings suggest that Bcl-2 family members may represent novel putative targets in the future treatment of prostate cancer.
c-RAS
The three cellular RAS genes (c-Ha-RAS, c-Ki-RAS), which encode a 21 kDa GTPaGDP-binding protein, 97 play an imortant role in cell proliferation and differentiation. 98 Activation of the c-RAS genes occurs following single-point mutations, or deregulated expression of the wild-type alleles. 99, 100 Several studies have evaluated the frequency of RAS mutations in prostate cancer (reviewed in reference 13). Activation of Ha-RAS by point-mutations was shown to be an infrequent event in the initiaition or the progression of prostate cancer in American men. In contrast, RAS mutations seem to occur at a signi®cant frequency ( $ 25 %) in Japanese men. These results suggest that there may be signifcant differences in the genetic events associated with prostate cancer in american men vs Japanese men. More studies to evaluate the role of RAS genes in prostate cancer are warranted
c-MYC
The c-MYC gene is located in chromosome 8, and it enclodes a nuclear phosphoprotein, which is involved in the regulation of cellular proliferation and differentiation. 101 Myc proteins are also effective inducers of apoptosis, which may both restrain inappropriate cell growth and maintain normal tissue homeostasis. 102 Most human tumours have mutations in MYC proto-oncogene family members, and thus deregulated MYC expression. 103 Expression of c-MYC has been shown to be negatively regulated by high concentrations of androgen. 104 Overexpression of c-MYC has been observed in BPH and prostatic carcinoma. 105 Interestingly, the band 8q24, to which MYC has been mapped, is commonly ampli®ed in prostate cancer. 24, 101, 106 Few studies have examined the role of MYC in prostatic carcinogenesis, but in general it has been associated with tumours of higher grade, and higher levels of c-MYC mRNA have been detected in prostate carcinomas when compared with BPH. 105, 107 
Growth factors and growth factors receptors
The prostate gland requires androgens for proliferation and maintenance of its function. 108 In addition to hormones, a variety of other molecules such as polypeptide growth factors, are involved in prostatic growth and differentiation (reviewed in reference 109). Polypeptide growth factors are generally produced locally and exert their effects either on the tissue in which they have been produced (autocrine action), or on adjacent tissues (paracrine action). There are ®ve main growth factors known to be involved in normal and abnormal prostatic growth, namely transforming factor a and b (TGF-a and TGF-b, respectively), epidermal growth factor (EGF), insulin-like growth factors I and II (IGF-I and IGF-II, respectively) and some members of the ®broblast growth factor family (FGF). Whereas TGF-a, EGF, and IGF are strong mitogens to prostate, TGF-b has a dual function in the regulation of prostatic growth. Human prostate sensitivity to androgens may be mediated by the production of polypeptide growth factors from stromal cells which act as direct intermediates of androgen action on epithelial cells. 110 The inhibitory effects of TGF-b1 in epithelial cells are opposed by EGF, IGF and FGF stimulation, thereby keeping the epithelial cell numbers constant. Therefore, polypeptide growth factors are both positive and negative regulators of prostatic growth and function.
TGF-b
TGF-b is a heat-and acid-stable 25kDa dimeric protein, and is a member of a superfamily consisting of ®ve isoforms, three of which are found in mammalian cells. 111 TGF-b1 binds to three types of receptors: type I contains a serineathreonine kinase domain and has been reported to transduce signals that promote the synthesis of matrix proteins; type II is also a serineathreonine kinase which mediates antiproliferative signals; and type III is a proteoglycan which binds to TGF-b1, but does not transduce growth factors signals. 112 TGF-b1 is a potent inhibitor of many types of epithelial cells in vitro, but paradoxically is expressed at higher than normal levels in a variety of tumours (reviewed in reference 109). TGFb1 is a pleiotropic growth factor, which has been shown to modulate proliferation and differentiation, but which can also stimulate angiogenesis, suppress the immune system, and stimulate invasion and metastasis. 113 TGFb-mediated modulation of cell proliferation is thought to be cell type-and concentration-dependent. For example, it has been shown to be mitogenic to most stromal cells, and inhibitory to most cells of epithelial origin. 109 The latent peptide can then be activated in vitro by acidi®ca-tion. 111 TGF-b has been shown to regulate the synthesis and turnover of components of the extracellular matrix, stimulate protease inhibitors, and to inhibit the tissue plasminogen activator. 113 Therefore, loss of responsiveness to TGF-b is believed to be an important factor in tumour formation, and indeed some physiological TGFb1 responses (such as growth inhibitory activity) are lost during malignancy. 114 It has been suggested that TGF-b1 inhibits proliferation by blocking Rb phosphorylation, thereby decreasing c-MYC expression and, consequently, proliferation. 115 Studies on prostate cancer indicate that advanced tumours escape the inhibitory effects of TGFb. 109 Therefore, administration of TGF-b is limited to the stages which precede the overexpression of this growth factor.
EGF and TGF-a
EGF and TGF-a signal through a common receptor, the EGF receptor (EGFR), as they share $ 35 % sequence homology. 116 Members of the EGF family of tyrosine kinase receptors are known to be involved in the regulation of cell growth and differentiation, and are found to be expressed in many types of cancers. 117 Although both share a number of biological effects, EGF is secreted both by normal and malignant cells, whereas TGF-a is predominantly secreted by tumour cells. 109 EGF has been shown to be mitogenic to prostate cells and accordingly, prostatic secretions have been found to contain the highest EGF levels of all human¯uids. 118 EGF is androgen-regulated, and hence, androgen withdrawal is followed by a decrease in EGF levels, which can nevertheless be restored by administration of minimal levels of testosterone. 119 Elevated levels of EGFR and TGF-a mRNA and protein have been observed in prostate cancer specimens compared with benign, secretory epithelium, and this has been associated with a more aggressive disease and a poor prognosis. 109, 120, 121 In addition, assessment of the relative expression and autocrine activation of the EGFR in normal and transformed prostatic epithelial cells has shown that human androgen-independent prostate cancer cell lines (PC-3 and DU145) exhibited higher levels of EGFR expression and autocrine phosphorylation than normal human prostatic epithelial cells, or human androgen-responsive prostate cancer cells (LNCaP). 122 It seems that autocrine activation of EGFR is a common feature of prostatic carcinoma cells in contrast to normal epithelial cells. The intracellular domain of the EGFR has been shown to have partial homology with ErbB2. 123 Interestingly, ERB B2 has been found to be mutated in a variety of cancers. There is also some evidence that the expression of EGFR increases with malignant potential. 109 This, in combination with a higher expression of EGF, may re¯ect an autocrine mechanism through which more aggressive androgen-independent cells overcome androgen-dependence. In addition, it has been suggested that the progression to the androgen-independent state may involve a switch in the predominant ligand from EGF to TGF-a. 124 In vitro studies using the DU145 cell line have shown that EGFR-mediated signals enhance cell transmigration of an extracellular matrix. This increased invasiveness has been shown to be independent of proteolytic degradation of the matrix 125 and not due to altered growth. 126 Therefore, it seems likely that activation of the EGFR may be important for the progression of prostate cancer. Blockade of the receptor-ligand interaction may offer alternative means of therapeutic intervention. 127 
IGF
The IGF system is characterised by a complex network between IGF-I and IGF-II, their receptors, high af®nity binding proteins (IGFBPs), and proteases, such as kallikreins, cathepsins and matrix metalloproteinases. 109, 128 IGFs have been shown to play critical roles in embryonic growth, and differentiation. 129 IGF-1 and IGF-II belong to a family of peptide hormones, which also includes insulin and relaxin. 130 Both interact with the insulin receptor (IR), as well as with speci®c receptors: type I receptor is a tyrosine kinase and binds both IGF-I and IGF-II; type II is structurally distinct and binds primarily the IGF-II. 131 IGF-I, which is secreted mainly by the liver, is also secreted by other tissues in response to growth hormone. 132 IGF-I and IGF-II are found circulating in the serum at higher concentrations than insulin but are prevented from binding to the IR by the IGFBPs, which sequester them away from the IR, facilitate their transport, and regulate their cellular functions (reviewed in reference 129). IGF-I and several IGFBPs, which are produced by normal and malignant prostate cells, act locally to stimulate cellular proliferation. 131 Mantzoros et al 133 have recently shown that although there was no relation between IGF-I and BPH, increased levels of IGF-I were associated with increased risk of prostate cancer. There is evidence that IGF-II may be replaced by IGF-I during malignant progression. This change in IGF expression has been shown to be accompanied by altered expression on IGFBP-2, which seems to be less detectable in prostatic tissues, but is elevated in serum. 134 As IGFBPs are positive and negative modulators of the activity of IGFs, it seems possible that altered expression of IGFBPs might also play a role in the progression of prostate cancer. Indeed, IGFBP-2 has been shown to be increased, and IGFBP-3 decreased in the serum of patients with prostate cancer. 135 IGFBP-3 is known to block IGF action and inhibit cell growth. IGFBP-3 production has been shown to be increased by cell growth-inhibitory agents, such as TGF-b and p53. Induction of apoptosis by this protein was shown to occur via a novel pathway independent of either p53 or the IGFaIGFR-mediated cell survival pathways. 136 There is recent evidence suggesting that inhibitory IGFBPs (such as IGFBP-4) may signi®-cantly delay the growth of malignant prostate epithelial cells and enhance the sensitivity of these cells to apoptosis. 137 As previously mentioned, prostate cancer selectively metastasises to bone, which is an environment rich in IGFs. This suggests an important role for the IGFaIGF-IR pathway in metastasis and provides a basis for targeting IGR-IR as a potential treatment for metastatic prostate cancer. 138 In addition, the IGF-I has been shown to synergise with androgens in the activation of the AR. 139 This may be of importance, especially in advanced prostate cancer, when testicular androgens are suppressed but small amounts of androgen are still supplied by the adrenals. 109 Both EGF and IGF-I are potent mitogens, which exert their actions through binding to their cell surface receptors. This initiates intracellular phosphorylation cascade(s), which lead to the activation of kinase cascades, such as the mitogen-activated protein kinase (MAPK), or the phosphatidylinositol-3 kinase (PI-3K) pathways. 74, 140, 141 It has recently been shown that selective blockade of the EGF receptor in prostate cancer cells does not only inhibit the action of EGF, but also IGF-I-induced activation of the MAPK pathway and the interaction with the PKA pathway, offering additional possibilities for therapeutical intervention in prostate cancer. 140 
FGF
The FGF family (also known as heparin-binding growth factor family) consists of at least 15 members, including acidic FGF (aFGFaFGF-1), basic FGF (bFGFaFGF-2), FGF-3 (Int-2), FGF-4 (Kaposis FGF), FGF-5, FGF-6, FGF-7 (keratinocyte growth factor, KGF), and FGF-8 (androgen-induced growth factor, AIGF) (reviewed in reference 142). FGFs have been shown to be major regulators of embryonic development, and their activities are dependent on the co-ordination of fundamental cellular functions, such as survival, replication, differentiation, adhesion, and motility, through effects on gene expression and the cytoskeleton. FGFs bind to receptor tyrosine kinases (FGFRs), heparin sulphate proteoglycans (HSPG), and a cysteine-rich FGF receptor (CFR). 142 The FGFs signal through complex signalling pathways, in which there is extensive cross-talk with the pathways utilised by IGF, and TGF-b. 142, 143 Four members (FGF-3 to FGF-6) have been shown to be oncogene products, and FGF-7 has been shown to be a growth factor for keratinocytes. 143 The ability of FGF-1 and FGF-2 to modulate the proliferation of endoepithelial cells re¯ects their angiogenic activity. 144 In the developing rat prostate, FGF-1 is highly expressed. 145 FGF-1 expression, however, starts decreasing after birth and it is undetectable at 35 weeks. Accordingly, in the human prostate, FGF-1 expression is either low or undetectable, whereas FGF-2 is highly expressed. 146 FGF-2 is not only mitogenic for prostatic cells, but it also seems to contribute to metastasis. The level of FGF-2 has been shown to be elevated in prostate tumours when compared with normal prostatic tissue, suggesting that it may indeed play a role in the development of prostatic neoplasms. 147 ± 149 FGF-8 has been shown to be overexpressed in prostate cancer and its expression has been correlated with histological grade. 150, 151 There is evidence suggesting that androgens can regulate TGF-b, and modulate the expression of FGF-2 and FGF-7, thereby regulating growth of the prostatic stroma and epithelium. 152 Therefore, altered expression of FGFs and their receptors is likely to contribute to prostate disease.
Interleukin 6
Interleukin 6 (IL-6) is a cytokine shown to be mitogenic for various tumours. [153] [154] [155] With the exception of tumour cells, which constitutively express IL-6, normal cells do not produce IL-6, unless appropriately stimulated. 156 Recently IL-6 has been shown to act as a paracrine and autocrine growth factor in human prostatic carcinoma in vitro. 157 It had, however, no growth effect on epithelial cells derived from BPH. 157 IL-6 is a multifunctional cytokine which exerts its effects through interaction with speci®c receptors expressed on the surface of target cells (IL-6Raagp130). Interestingly, the adaptor protein Shc has been shown to mediate IL-6 signalling by interacting with gp130 and Jak2 kinase and it has been suggested that Shc proteins may act as a functional link between the Jak2 and Ras pathways of IL-6 signal transduction. 158 Moreover, in addition to blocking Fas-induced cell death and SAPKaJNK activation in multiple myeloma cells, 159 IL-6 has also been shown to mediate resistance of androgenindependent cell lines to cytotoxic drugs. 160 Furthermore, Twillie et al 161 have shown that IL-6 is a candidate mediator of prostate cancer morbidity and a candidate marker of the disease activity for prospective clinical testing.
Neuropeptides
There is accumulating evidence from experiments with tumour models that neuropeptides, such as bombesin, neurotensin, and endothelin-1, can in¯uence the growth of prostatic tumour cells. 162, 163 Neuroendocrine cells can be found in normal, hyperplastic and neoplastic prostatic tissues. Adenocarcinomas of the prostate which express neuroendocrine properties do not respond to androgen ablation therapy. 164 A possibility is that the neuroendocrine cells in prostate cancers do not contain the androgen receptor, and are therefore primarily androgen independent. In addition, some of the neuropeptides secreted by the neuroendocrine cells may act as growth factors by activation of membrane receptors in an autocrine-paracrine fashion, or by ligand-independent activation of the androgen receptor in neighbouring non-neuroendocrine cells. 163 Elevated levels of neuropeptides and neuroendocrine markers in the serum of patients have been associated with poorer survival. 165 Androgen-independent cells have been reported to express bombesin, neurotensin and endothelin-1 receptors, 162, 166, 167 and receptor antagonists for the neuropeptides have been shown to inhibit the growth of prostate tumour xenografts. 168 Neuropeptides are mitogenic for androgen-independent prostate cancer cells, and thus contribute to androgen-independent growth. Recently, it has been shown that neuropeptides can stimulate secretory activity of the type IV collagenases matrix metalloprotease (MMP)-2 and MMP-9 in human prostate cancer cell lines, which have been previously linked with a wide array of biological activities, including tumour invasion, metastasis, and angiogenesis. 169 Neutral endopeptidase 24.11 (NEP, neprisylin, enkaphalinase, CD10, EC 3.4.24.11) is a zinc-dependent metalloproteinase which inactivates a variety of physiologically active peptides implicated in the growth of androgen-independent prostate cancer (for example, bombesin, neurotensin and endothelin-1). Cell-surface peptidases play a key role in the control of growth and differentiation by modulating the activity of peptide factors and regulating their access to adjacent cells. 170 The inactivation of such peptides causes a reduction in the local concentrations available for receptor binding and signal transduction. 171 Therefore, loss of NEP results in the failure to inactivate the active peptides. 172 Recently, Papandreou et al 172 have shown that NEP expression and catalytic activity are lost in vitro in androgen-independent but not androgen-dependent prostate cancer cell lines. Because decreased NEP expression is thought to be facilitated by the elimination of androgens, NEP loss may play an important role in the development of androgen-independent prostate cancer by allowing prostate cancer cells to use mitogenic peptides as an alternative source to androgen in order to stimulate cell proliferation.
Apoptosis in prostate cancer
Although life and death seem to be opposing phenomena, from a biochemical viewpoint, they are undissociable. The total number of cells in a multicellular organism is kept remarkably constant because of the ®ne balance which is maintained between cell generation via mitosis and cell death via apoptosis. Apoptosis is an active form of cell death, induced both by endogenous and exogenous stimuli, and it occurs under physiological conditions. 173, 174 Morphologically, it is characterised by cellular features such as membrane blebbing, cell shrinkage and chromatin condensation. 175 Intracellular events include various types of DNA fragmentation, 176 cytoskeletal alterations and protease activation (reviewed in reference 177). There is increasing evidence that apoptosis is a cellular default setting, which must be actively suppressed (for example by growth factors, anti-apoptotic proteins) for the cell to survive.
The remarkable ability of prostate cancer cells to survive apoptosis has led to the search for the alternative pathways which allow them to escape death. Indeed, there has been a close association between apoptosis and prostate cancer initiation, metastasis and response to treatment. 178 For example, progression of localised cancer to metastatic, androgen-independent prostate cancer has been associated with increased Bcl-2 expression. It is worthwhile pointing out that Bcl-2 expression is not an absolute requirement for progression, as 83% of lymph node metastases, and 47% of bone metastases in hormonally treated patients were negative for Bcl-2, as well as 58% of bone metastases in patients who had failed hormonal therapy. 179 However, prostate cancer cells still retain the potential to undergo apoptosis induced by a wide range of stimuli. Tang et al 178 
Medical approaches in the management of prostate cancer
Nearly all American men develop histological benign prostatic hyperplasia (BPH), at least half develop obstructive or hyper-reactive urinary symptoms related to this, and half of these require either medical, or surgical intervention to relieve their symptoms. 180 In addition, 10% of North American men will develop prostate cancer. 181 Androgens are not only required for the differentiation of the male internal and external genitalia during embryogenesis, but are also essential for the development and maintenance of secondary sexual characteristics. Testosterone can be converted to a more potent androgen, dihydrotestosterone (DHT), by 5-a-reductase, in a variety of androgen-dependent target tissues, including the prostate. When the androgens bind to the AR, the AR becomes activated, dimerises, and locates to the nucleus where it binds speci®c sequences in the regulatory regions of target genes. 182 Androgens are the most potent mitogens to the prostate. Indeed, androgen depletion by orchidectomy results in massive apoptosis in prostatic epithelial cells, causing tissue involution. 183 Elevated levels of testosterone have been shown to induce prostate cancer in laboratory rodents. 184 Therefore, androgens are believed to play pivotal roles in prostatic carcinogenesis. The epidemiological data are, however, limited and con¯icting. 185, 186 Gann et al 187 have shown that higher levels of testosterone, and lower levels of oestradiol and sex hormone-binding globulin (SHBG), a protein which binds $ 56% of circulating testosterone, were associated with increased risks of prostate cancer. In contrast, a study by Nomura et al 188 did not con®rm this ®nding. Further studies are needed to determine whether it is an imbalance of several hormones, or some differences in hormonal metabolism or androgena oestrogen receptors that is in¯uencing prostate cancer risk. The mitogenic action of androgen in benign and malignant prostate cells is thought to be mediated by different growth factors via paracrine or autocrine mechanisms. 189 While the action of androgens in benign prostatic epithelial cells requires the participation of stromal cells though an autocrine mechanism, malignant cells can avail of alternative pathways.
When all the clinical and laboratorial evidence is made available, $ 80% of patients with prostate cancer have either locally advanced, or metastatic disease. 190 Such patients usually receive palliative treatment with some form of hormonal manipulation, which will abrogate the stimulatory effects of androgen. 191 Reduction of LHRH release following negative feedback on the hypothalamus by oestrogens reduces LH production by pituitary glands and testosterone production by testicular Leydig cells. Therefore, LHRH analogues have produced alternative options for hormone-ablation therapy, without having cardiovascular side-effects. 180 The management of patients with localised early prostate cancer is more controversial, especially in the younger age group.
In general, well differentiated tumours have a very good prognosis, seldom progress, and have a survival which corresponds to the life-expectancy of normal controls matched for age. 190 In contrast, patients with multifocal and poorly differentiated tumours usually have a bad prognosis due to early progression and a high incidence of lymph node metastases.
Although initially the prostate cancer cells respond to androgen-ablation by both involution (apoptosis) and stabilisation, populations of hormone-refractory cells emerge. This is invariably fatal because no effective systemic therapy currently exists. Because no genetic alteration has been consistently associated with prostate cancer, molecular mechanism-based therapies are dif®cult to design.
Successful treatment of slow-growing androgen-independent prostate cancer cells will probably require simultaneous anti-proliferative chemotherapy targeted at the small number of dividing cancer cells, and some sort of additional therapy targeted at increasing the low apoptosis rate of the majority of androgen-independent cancer cells not proliferating within the prostate cancer. 192 There are at least three cell proliferation independent methods which can be used to increase the apoptotic rates of androgen-independent prostate cancer cells. 192 The ®rst approach is to use the host immune system to evoke, or enhance a cytotoxic anti-tumour response. Because both the growth and metastatic potential of a tumour are dependent on angiogenesis, the second approach is to block the host development of tumour blood supply.
Finally, the third approach is to manipulate apoptosis, and force the tumour cells to commit`suicide'. However, due to the complexity of prostatic cancer, successful treatment of the disease is likely to require a multimodality therapy involving cytokines (immunotherapy), cytotoxic drugs (chemotherapy) andaor hormonal ablation.
Recently, 9-aminocamptothecin, a topoisomerase I inhibitor, has been shown to be active against hormonerefractory prostate cancer cells, and it is being tested in a Phase II clinical trial. 193 In addition, we have recently shown that a combinatory treatment of androgen-independent DU145 cells with sublethal concentrations of camptothecin and very low concentrations of anti-Fas IgM, will kill 75 ± 95% of a cell culture population in 24 h. 194 Fas (CD95aAPO-1) belongs to the nerve growth factoratumour necrosis factor (NGFaTNF) receptor family, and its main function is the induction of apoptosis in a variety of cell types. 195, 196 The prostatic epithelium is one of the few tissues to co-express Fas and FasL, along with other immune privileged tissues which are marked by apoptotic turnover, and there is evidence for an in vivo role for Fas signalling in the hormonal regulation of the normal, differentiated prostatic epithelium. 197 Recently, it has been shown that Fas expression is highly variable among human prostate cancer cell lines, and that it does not correlate with the sensitivity of the cells to anti-Fasmediated apoptosis. 52, 198 Therefore, although Fas expression is necessary, it is not suf®cient to mediate apoptosis through this pathway. 198 Hedlund et al 198 have shown that prostate cancer cell lines which were derived from primary sites were sensitive to Fas-mediated apoptosis, whereas prostate cancer cell lines which were derived from distant metastases were resistant. These data are in accordance with the in vivo loss of apoptotic potential during the progression of prostate cancer, although it is still unclear if Fas signalling plays a direct role in this phenomenon. Cytokines can exert cytostatic and immuno-modulatory effects on carcinoma cells, and there is evidence that cytokine treatment (for example TNF-a and IFN-g) can effectively alter prostate carcinoma properties thought to be closely associated with tumour angiogenesis and metastasis. 199 Hence, the implications of these results may be far reaching, as they suggest that a combination of chemotherapy and immunotherapy may offer a considerable advantage in the treatment of androgen-independent prostate cancers. Moreover, if loss of sensitivity to Fas signalling is shown to pay a direct role in the progression of prostate cancer, then restoring the cells' susceptibility to Fas ligation will be of obvious importance for future medical intervention in prostate cancer patients. However, potential risks (such as toxicity) of such an approach must be evaluated before one can aim at using them as part of a regimen for prostate cancer therapy. It is anticipated that the elucidation of additional apoptotic pathways relevant to prostate cancer cells will aid the design of more effective therapeutic regimes, and help us to improve the duration and the quality of life of prostate cancer patients in the future.
